- Home
- APLT vs ETW Comparison
APLT vs ETW Comparison
Compare APLT & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APLT | ETW |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 999.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | APLT | ETW |
|---|---|---|
| Price | $0.10 | $9.24 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.25 | N/A |
| AVG Volume (30 Days) | ★ 10.8M | 284.6K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | $124.18 | N/A |
| Revenue Next Year | $66.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $6.96 |
| 52 Week High | $1.50 | $8.49 |
Technical Indicators
Market Signals| Indicator | APLT | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 27.66 | 54.82 |
| Support Level | $0.10 | $9.16 |
| Resistance Level | $0.11 | $9.34 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 25.40 | 60.00 |
Price Performance
Historical ComparisonAbout APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.